Clinical Trial Search

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Program Enrollment Rate (%) — 14 Percentage of participants

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin

Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants

Primary: Glucose — -21.55; 1.92 mg/dL

Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c

Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change

Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants

Primary: Disposition Index — 0.023; 0.149 index

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl

Primary: Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 6.83; 7.15; 6.84 millimoles per Liter…

Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values

Primary: Self-Care Activities: Healthy Eating — 4.23; 4.67; 4.61; 4.60 days/week (min: 0 days; Max: 7 days)

Primary: Change in HgbA1c — -1.9 percentage of glycosylated hemoglobin

Primary: Diabetes Remission Rate — 3; 6 Participants — p=<0.0001

Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001

Primary: Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint — 18.5 percentage of participants

Primary: Change From Baseline Hemoglobin A1c at 12 Weeks — -0.3; -0.1 % of HbA1c

Primary: Change in HbA1c From Baseline — 0.015; 0.030 % (HbA1c) — p=0.933

Primary: Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6% — 4; 4 Participants

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.91; -1.87 percent (%) glycated hemoglobin — p=0.716